Monoclonal antibody biosimilars are shaping the next growth phase through expanding biologic competition, manufacturing advances, and improved market access.
Biosimilar supply chains need to build resilient global manufacturing and distribution networks while reducing disruption and supply risks to achieve success.
Explore how AI in biosimilar development can accelerate comparability studies through advanced analytics, machine learning, and automated data analysis tools.
Biosimilar manufacturing processes are using advanced bioprocessing, process optimisation and automation to reduce development and production costs globally.
